Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

High neutrophil-to-lymphocyte ratio does not predict MGUS to myeloma progression but is associated with worse survival as a marker of global inflammation

Virginia Hsiao, Colin Tang-Whitmore, Qing Cao et al. Nov 03, 2025 pp. 5742-5742 10.1182/blood-2025-5742

Abstract BACKGROUND Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal plasma cell disor...

Cost savings across bone marrow testing strategies in persons with suspected monoclonal gammopathy of undetermined significance

Manraj Sra, Karthik Chetlapalli, Satoko Ito et al. Nov 03, 2025 pp. 4409-4409 10.1182/blood-2025-4409

Abstract Introduction: Monoclonal gammopathy of undetermined significance (MGUS) affects over 2 million individuals aged ≥70 in the US. Earl...

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

Shree Allada, Richa Parikh, Ajay Nooka et al. Nov 03, 2025 pp. 4078-4078 10.1182/blood-2025-4078

Abstract Background CAR-HEMATOTOX score, a cumulative score of key independent laboratory variables, is a clinical surrogate of bone marrow r...

Measles vaccine-induced sero-protection among children with sickle cell anemia

Alexandra Power-Hays, Abigail Kincaid, Kathryn McElhinney et al. Nov 03, 2025 pp. 1168-1168 10.1182/blood-2025-1168

Abstract Introduction: Measles is a highly contagious and vaccine-preventable disease with increasing infection rates across the United Stat...

First results of exagamglogene autotemcel in pediatric patients aged 5-11 years with transfusion-dependent β-thalassemia or sickle cell disease with recurrent severe vaso-occlusive crises

Haydar Frangoul, Josu de la Fuente, Mattia Algeri et al. Nov 03, 2025 pp. 379-379 10.1182/blood-2025-379

Abstract Background: Exagamglogene autotemcel (exa-cel) is a one-time, autologous cell therapy that reactivates fetal hemoglobin (HbF) synth...

Comparison of outcomes in pediatric patients with acute leukemia undergoing allogeneic HLA-haploidentical hematopoietic stem cell transplantation (HSCT) after in vitro a/b T- and CD19-cell depletion or In Vivo administration of post-transplant cyclophosphamide: An EBMT pediatric working party study

Daria Pagliara, Pietro Merli, Jacques-Emmanuel Galimard et al. Nov 03, 2025 pp. 515-515 10.1182/blood-2025-515

Abstract Background HLA-haploidentical relatives are increasingly used to transplant children with acute leukemia (AL) requiring an allograf...

Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment

Fu-li Li, Jia Cong, Liang Wang Nov 03, 2025 pp. 1941-1941 10.1182/blood-2025-1941

Abstract Background: Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who fail bispecific antibody (BsAb) therapy...

A novel method for molecular subtyping diffuse-large B-cell lymphoma using whole-exome sequencing

Daniel Kerr, Yuefan Huang, Antony Tin et al. Nov 03, 2025 pp. 4336-4336 10.1182/blood-2025-4336

Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of non-Hodgkin lymphoma, with 30-40% of case...

Chromodomain helicase DNA binding protein CHD2 interacts with TET2 and regulates lineage defining transcription in hematopoietic stem and progenitor cells

Songa Bae, Xiaorong Gu, Mamta Sumi et al. Nov 03, 2025 pp. 3237-3237 10.1182/blood-2025-3237

Abstract Introduction. TET2 mutations (TET2MT) are among the most frequent somatic lesions in myeloid malignancies, found at ~30% in MDS/AML...

The burden of hematological malignancies in Latin America and the Caribbean: A 30-year global burden of disease analysis

Héctor Alejandro Vaquera Alfaro, Alejandra De Las Fuentes, Andres Noyola-Perez et al. Nov 03, 2025 pp. 4615-4615 10.1182/blood-2025-4615

Abstract Background Hematologic malignancies (HM) such as leukemia, non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), multiple myeloma (MM)...

Semaphorin 4D and interleukin 1beta-complement cascade axis are key drivers of disease progression in multiple myeloma

Ioannis Ntanasis-Stathopoulos, Panagiota-Efstathia Nikolaou, Charalampos Filippatos et al. Nov 03, 2025 pp. 3925-3925 10.1182/blood-2025-3925

Abstract Background and aims: Myeloma bone disease (MBD) is a common and clinically significant manifestation, observed in most patients at t...

Maintenance with hypomethylating agent + venetoclax after intensive induction chemotherapy in patients with newly diagnosed Acute Myeloid Leukemia

Georgio Medawar, Kevin Graf, Jean-Sebastien Anoma et al. Nov 03, 2025 pp. 6960-6960 10.1182/blood-2025-6960

Abstract Background Consolidative therapy with high/intermediate-dose cytarabine is standard practice for fit patients w...

Unbiased in-depth surfaceome profiling of Acute Myeloid Leukemia reveals novel immunotherapy targets beyond canonical membrane proteins

Abhilash Barpanda, Szu-Ying Chen, Benson George et al. Nov 03, 2025 pp. 385-385 10.1182/blood-2025-385

Abstract Background Despite recent therapeutic advances, 5-year survival for AML in adults remains ~35% (SEER estimate). Immunotherapies hav...

Trends in mortality and comorbidity of type 2 diabetes mellitus among u.S. adultswith multiple myeloma: A CDC wonder-based analysis, 1999–2023

Hakim Wazir, Aqsa Shaikh, Swathi Cherukuri et al. Nov 03, 2025 pp. 8115-8115 10.1182/blood-2025-8115

Abstract Background : Type 2 diabetes and Multiple myeloma are becoming a growing cause of worry among aging populations...

External validation of an online predictive model for myelodysplastic syndrome

Nina Castrogiovanni, Beau Bouliane, Candy Niu et al. Nov 03, 2025 pp. 2660-2660 10.1182/blood-2025-2660

Abstract Background: Single-lineage cytopenia is highly prevalent in the elderly population, with common causes including nutritional defici...

Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms

Qingmei Han, Rumeng Li, Bingbing Wen et al. Nov 03, 2025 pp. 7286-7286 10.1182/blood-2025-7286

Abstract Introduction: Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of diseases, including primary myelofibrosis (P...

FLP-R: A clinical prediction model for follicular lymphoma Prognosis in the Relapsed/refractory setting

Matthew Maurer, Melissa Larson, Urshila Durani et al. Nov 03, 2025 pp. 5354-5354 10.1182/blood-2025-5354

Abstract Background: Prognostication for patients with non-transformed relapsed/refractory (R/R) follicular lymphoma (FL) is not well define...

Comparative performance of clinical versus genomic machine learning prognostic models in AML: A prisma-guided systematic review and meta-analysis

Xiaoyi Zhang, Abhishek Kumar, Toru Yoshino et al. Nov 03, 2025 pp. 656-656 10.1182/blood-2025-656

Abstract Background: Machine learning and deep learning models are increasingly used to refine prognosis in acute myeloid leukemia, but clin...

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Sanam Loghavi, Chenxuan Zang, Ziyi Li et al. Nov 03, 2025 pp. 3848-3848 10.1182/blood-2025-3848

Abstract Background: Extramedullary disease (EMD) in chronic myelomonocytic leukemia (CMML) patients (pts) remains poorly characterized with...

Unsupervised clustering of RNA sequencing data identifies a novel XBP1-mutated subtype of B-cell acute lymphoblastic leukemia (B-ALL)

Qian Jiang, Chengcheng Yan, Jianfeng Yao et al. Nov 03, 2025 pp. 6884-6884 10.1182/blood-2025-6884

Abstract 1. Research Objectives :With the application of RNA sequencing (RNA-seq) in B-ALL, the diagnosis of B-ALL has entered the era of pr...

Cell-free DNA (cfDNA) and plasma proteomics reveal inflammatory heterogeneity in vaso-occlusive crises in sickle cell disease (SCD).

Magdalene Ford, Zhuangzhuang Geng, Susanna Ostrowski et al. Nov 03, 2025 pp. 2930-2930 10.1182/blood-2025-2930

Abstract Background: SCD is characterized by chronic hemolytic anemia and recurrent vaso-occlusive crises (VOCs), which are a leading cause...

The platelet variability index tool to determine the likelihood of immune thrombocytopenia (ITP): User testing and tool refinement

Syed Mahamad, Na Li, Bianca Clerici et al. Nov 03, 2025 pp. 3037-3037 10.1182/blood-2025-3037

Abstract Introduction The diagnosis of immune thrombocytopenia (ITP) is challenging due to the lack of a reliable diagno...

Temporal trends and future projections of sepsis mortality in leukemia: A nationwide analysis of demographic and geographic disparities (1999–2030)

Haseeb Tareen, Allah Dad, Rana Uzair Ahmad et al. Nov 03, 2025 pp. 8170-8170 10.1182/blood-2025-8170

Abstract Background: Leukemia is a hematologic malignancy characterized by the uncontrolled proliferation of leukocytes, and it is broadly c...

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Ondrej Venglar, Daniel Bilek, Eva Radova et al. Nov 03, 2025 pp. 5720-5720 10.1182/blood-2025-5720

Abstract Background: Anti-CD38 monoclonal antibodies (mAbs) have become a standard part of multiple myeloma (MM) therapy. Their activity is...

PARP inhibition by talazoparib results in leukemia cell death via induction of myeloid differentiation

Leslie Martinez-Gutierrez, Marianna Giorgi, Julia Kichina et al. Nov 03, 2025 pp. 3281-3281 10.1182/blood-2025-3281

Abstract Background: Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy characterized by the uncontrolled proliferation o...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page